We assumed that if LTα3 played an important role in the clinical course of RA patients, cycling from anti-TNF monoclonal antibody to ETA, which neutralizes both TNF and LTα3, would be beneficial. The gene discussed is TNF; the disease is rheumatoid arthritis.